Literature DB >> 6780363

Quantitative studies of very low density lipoprotein: conversion to low density lipoprotein in normal controls and primary hyperlipidaemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolaemia.

E D Janus, A Nicoll, R Wootton, P R Turner, P J Magill, B Lewis.   

Abstract

Autologous 131I-labelled very low density lipoprotein (VLDL) and 125I-labelled low density lipoprotein (LDL) were injected into seven normal subjects and twenty-eight genetically classified hyperlipidaemic patients to quantitate lipoprotein interconversion. The apoprotein B specific activity--time curves for VLDl and intermediate density lipoprotein (IDL, density = 1 . 006--1 . 019 g/ml) intersected at or before the IDL-B maximum in thirty-one studies (five normal controls and twenty-six hyperlipidaemic subjects) implying that all IDL-B may be derived from VLDL-B. The fractional conversion of VLDL-B to LDL-B (density 1 . 019--1 . 063 g/ml) following a simultaneous spike injection of 131I-VLDL and 125-LDL was obtained by deconvolution of the 125I and 131I-LDL-B activity curves. 21--65% (mean = 44%) of VLDL-B was converted to LDL-B in twenty-three subjects studied. The mean conversion time ranged from 10 to 24 h in ten normotriglyceridaemic subjects and from 19 to 42 h (mean = 33 h) in twelve hypertriglyceridaemic subjects. In one patient with broad-beta disease the mean conversion time was 55 h. LDL-B production from VLDL-B and total LDL-B synthetic rate were essentially equal in normal controls and normocholesterolaemic subjects and in the patient with broad-beta disease. But in all six patients with familial hypercholesterolaemia LDL-B synthetic rate significantly exceeded LDL-B production from VLDL-B, indicating direct secretion of 20--72% of LDL-B at a rate which correlates positively with plasma LDL concentration. Three of five patients with familial combined hyperlipidaemia showed a lesser but nevertheless significant direct secretion of LDL-B.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6780363     DOI: 10.1111/j.1365-2362.1980.tb02075.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  23 in total

1.  Low density lipoprotein heterogeneity in spontaneously hypercholesterolemic pigs.

Authors:  S T Cooper; R J Aiello; W J Checovich; A D Attie
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

2.  The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients.

Authors:  R W James; D Pometta
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

3.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

4.  Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.

Authors:  J M Bard; G Luc; P Douste-Blazy; P Drouin; O Ziegler; B Jacotot; C Dachet; J L De Gennes; J C Fruchart
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia.

Authors:  B Teng; A D Sniderman; A K Soutar; G R Thompson
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

6.  Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.

Authors:  H N Ginsberg; N A Le; J C Gibson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 7.  The lipoproteins: predictors, protectors, and pathogens.

Authors:  B Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-22

8.  Splanchnic metabolism of plasma apolipoprotein B: studies of artery-hepatic vein differences of mass and radiolabel in fasted human subjects.

Authors:  P R Turner; N E Miller; C Cortese; W Hazzard; J Coltart; B Lewis
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

9.  Significance of low density lipoprotein production in the regulations of plasma cholesterol level in man.

Authors:  Y A Kesaniemi; S M Grundy
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

10.  Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease.

Authors:  Y A Kesäniemi; W F Beltz; S M Grundy
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.